ISTA Pharmaceuticals: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
'''ISTA Pharmaceuticals''' was | {{DISPLAYTITLE:ISTA Pharmaceuticals}} | ||
== Overview == | |||
[[File:Ista_logo.png|thumb|right|150px|Logo of ISTA Pharmaceuticals]] | |||
'''ISTA Pharmaceuticals''' was a pharmaceutical company that specialized in the development and commercialization of therapies for diseases and conditions of the eye. The company was known for its focus on ophthalmology and had a range of products aimed at treating various eye disorders. | |||
== History == | == History == | ||
ISTA Pharmaceuticals was founded with the mission to address unmet medical needs in the field of ophthalmology. Over the years, the company developed a portfolio of products that targeted conditions such as [[glaucoma]], [[dry eye syndrome]], and [[allergic conjunctivitis]]. | |||
ISTA Pharmaceuticals was founded in | |||
== Products == | == Products == | ||
ISTA Pharmaceuticals developed several notable products, including: | |||
* '''Bromday''' - A nonsteroidal anti-inflammatory drug (NSAID) used to treat postoperative inflammation and reduce pain in patients who have undergone cataract surgery. | |||
* '''Xibrom''' - Another NSAID indicated for the treatment of inflammation and pain associated with cataract surgery. | |||
* '''Bromday''' | * '''Vitrase''' - An enzyme used as a spreading agent to facilitate the dispersion and absorption of other injected drugs. | ||
* '''Xibrom''' | |||
* ''' | |||
== | == Acquisition == | ||
In 2012, ISTA Pharmaceuticals was acquired by [[Bausch + Lomb]], a leading global eye health company. This acquisition allowed Bausch + Lomb to expand its portfolio of ophthalmic pharmaceuticals and enhance its research and development capabilities in the field of eye care. | |||
== Research and Development == | |||
ISTA Pharmaceuticals was committed to innovation in ophthalmology. The company invested in research and development to create new therapies for eye diseases. Their R&D efforts were focused on improving existing treatments and developing new solutions for conditions such as [[macular degeneration]] and [[diabetic retinopathy]]. | |||
== | == Impact on Ophthalmology == | ||
The contributions of ISTA Pharmaceuticals to the field of ophthalmology were significant. By providing effective treatments for common eye conditions, the company helped improve the quality of life for many patients. Their focus on eye health and dedication to innovation set a standard in the industry. | |||
== Related pages == | |||
* [[Bausch + Lomb]] | |||
* [[Ophthalmology]] | |||
* [[Pharmaceutical industry]] | |||
[[Category:Pharmaceutical companies | [[Category:Pharmaceutical companies]] | ||
[[Category: | [[Category:Ophthalmology]] | ||
Latest revision as of 11:04, 15 February 2025
Overview[edit]
ISTA Pharmaceuticals was a pharmaceutical company that specialized in the development and commercialization of therapies for diseases and conditions of the eye. The company was known for its focus on ophthalmology and had a range of products aimed at treating various eye disorders.
History[edit]
ISTA Pharmaceuticals was founded with the mission to address unmet medical needs in the field of ophthalmology. Over the years, the company developed a portfolio of products that targeted conditions such as glaucoma, dry eye syndrome, and allergic conjunctivitis.
Products[edit]
ISTA Pharmaceuticals developed several notable products, including:
- Bromday - A nonsteroidal anti-inflammatory drug (NSAID) used to treat postoperative inflammation and reduce pain in patients who have undergone cataract surgery.
- Xibrom - Another NSAID indicated for the treatment of inflammation and pain associated with cataract surgery.
- Vitrase - An enzyme used as a spreading agent to facilitate the dispersion and absorption of other injected drugs.
Acquisition[edit]
In 2012, ISTA Pharmaceuticals was acquired by Bausch + Lomb, a leading global eye health company. This acquisition allowed Bausch + Lomb to expand its portfolio of ophthalmic pharmaceuticals and enhance its research and development capabilities in the field of eye care.
Research and Development[edit]
ISTA Pharmaceuticals was committed to innovation in ophthalmology. The company invested in research and development to create new therapies for eye diseases. Their R&D efforts were focused on improving existing treatments and developing new solutions for conditions such as macular degeneration and diabetic retinopathy.
Impact on Ophthalmology[edit]
The contributions of ISTA Pharmaceuticals to the field of ophthalmology were significant. By providing effective treatments for common eye conditions, the company helped improve the quality of life for many patients. Their focus on eye health and dedication to innovation set a standard in the industry.
